Obesity Medicine 2025 - Updates in Obesity Management and Cardiometabolic Health (Recorded)
Obesity is associated with cardiovascular disease. Most recently, the American Heart Associated described a new syndrome - Cardiovascular-Kidney-Metabolic (CKM) Syndrome, characterized by pathophysiologic interactions among metabolic disease, CKD, and the CV system, leading to multiorgan dysfunction and adverse CV outcomes. In this session, we will review the impact of obesity management using incretin therapies on cardiovascular outcomes. Attendees will learn about the relationship between obesity and adverse cardiovascular outcomes, review the newly described CKM syndrome, and understand how incretin therapies can improve cardiovascular outcomes
CME/CE Expiration Date: 4/27/28
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
Yael Mauer, MD, MPH, DABOM
Available Credit
- 1.00 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.